MIT Libraries logoDSpace@MIT

MIT
View Item 
  • DSpace@MIT Home
  • MIT Open Access Articles
  • MIT Open Access Articles
  • View Item
  • DSpace@MIT Home
  • MIT Open Access Articles
  • MIT Open Access Articles
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding

Author(s)
Andrews, Lawrence P; Somasundaram, Ashwin; Moskovitz, Jessica M; Szymczak-Workman, Andrea L; Liu, Chang; Cillo, Anthony R; Lin, Huang; Normolle, Daniel P; Moynihan, Kelly Dare; Taniuchi, Ichiro; Irvine, Darrell J; Kirkwood, John M; Lipson, Evan J; Ferris, Robert L; Bruno, Tullia C; Workman, Creg J; Vignali, Dario AA; ... Show more Show less
Thumbnail
DownloadAccepted version (2.089Mb)
Open Access Policy

Open Access Policy

Creative Commons Attribution-Noncommercial-Share Alike

Terms of use
Creative Commons Attribution-Noncommercial-Share Alike http://creativecommons.org/licenses/by-nc-sa/4.0/
Metadata
Show full item record
Abstract
Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works Mechanisms of resistance to cancer immunotherapy remain poorly understood. Lymphocyte activation gene–3 (LAG3) signaling is regulated by a disintegrin and metalloprotease domain-containing protein–10 (ADAM10)–and ADAM17-mediated cell surface shedding. Here, we show that mice expressing a metalloprotease-resistant, noncleavable LAG3 mutant (LAG3NC) are resistant to PD1 blockade and fail to mount an effective antitumor immune response. Expression of LAG3NC intrinsically perturbs CD4+ T conventional cells (Tconvs), limiting their capacity to provide CD8+ T cell help. Furthermore, the translational relevance for these observations is highlighted with an inverse correlation between high LAG3 and low ADAM10 expression on CD4+ Tconvs in the peripheral blood of patients with head and neck squamous cell carcinoma, which corresponded with poor prognosis. This correlation was also observed in a cohort of patients with skin cancers and was associated with increased disease progression after standard-of-care immunotherapy. These data suggest that subtle changes in LAG3 inhibitory receptor signaling can act as a resistance mechanism with a substantive effect on patient responsiveness to immunotherapy.
Date issued
2020
URI
https://hdl.handle.net/1721.1/133023
Department
Massachusetts Institute of Technology. Department of Biological Engineering; Koch Institute for Integrative Cancer Research at MIT
Journal
Science Immunology
Publisher
American Association for the Advancement of Science (AAAS)
Citation
Andrews, Lawrence P, Somasundaram, Ashwin, Moskovitz, Jessica M, Szymczak-Workman, Andrea L, Liu, Chang et al. 2020. "Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding." Science Immunology, 5 (49).
Version: Author's final manuscript

Collections
  • MIT Open Access Articles

Browse

All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

My Account

Login

Statistics

OA StatisticsStatistics by CountryStatistics by Department
MIT Libraries
PrivacyPermissionsAccessibilityContact us
MIT
Content created by the MIT Libraries, CC BY-NC unless otherwise noted. Notify us about copyright concerns.